Pemvidutide Reconstitution Calculator
Enter the amount you want to measure. The vial buttons will highlight which vial strengths create cleaner syringe-unit measurements.
What amount do you need?
Type the target amount, then choose mg or mcg. Example: 2mg or 500mcg.
Syringe size:
Possible vial strengths:
Best Match
Good Match
Usable
Harder to Measure
Example Pemvidutide Titration Schedule
| Parameter | Details |
|---|---|
| Dosage | 1.2 mg, 1.8 mg, or 2.4 mg per injection |
| Route | Subcutaneous (SC) |
| Frequency | Once weekly |
| Cycle Length | 24–48 weeks (clinical trials) |
| Half‑life | Extended (~7 days) via EuPort™ albumin-binding domain |
| Titration | None required (direct start at target dose) |
Possible vial strengths:
What Is It?
Pemvidutide
Dual GLP-1 / glucagon agonist in metabolic research.
Bacteriostatic Water
Sterile water containing a bacteriostatic preservative, commonly used when preparing multi-use research vials.
How To Mix Pemvidutide
1
CleanUse alcohol swabs to clean the tops of both vials.
2
Draw BAC WaterDraw the selected amount of bacteriostatic water.
3
Inject SlowlyAdd the liquid slowly down the side of the vial.
4
Swirl GentlyDo not shake. Swirl gently until dissolved.
5
Store ProperlyStore as directed and protect from heat and light.
Best Practices & Common Mistakes
Best Practices
- Use sterile technique.
- Protect from light and heat.
- Store refrigerated when appropriate.
- Use clean syringe-unit math before measuring.
Common Mistakes
- Confusing milligrams with milliliters.
- Choosing an option with awkward decimal units.
- Using too little liquid for very small measurements.
- Shaking the vial aggressively.
Pemvidutide Storage & Handling
Lyophilized Powder: −20°C (−4°F) for long-term storage (up to 24 months). Refrigeration 2–8°C (36–46°F) for short-term use (up to ~3 months). Original sealed vial in the freezer is safest.
Reconstituted Solution: 2–8°C (36–46°F), use within ~7–14 days. Keep sealed, avoid light, and do not repeat freeze-thaw cycles.
Reconstituted Solution: 2–8°C (36–46°F), use within ~7–14 days. Keep sealed, avoid light, and do not repeat freeze-thaw cycles.
Frequently Asked Questions
Pemvidutide is an investigational peptide-based GLP-1/glucagon dual receptor agonist developed by Altimmune. It is being studied for obesity and MASH, but it is not FDA-approved or commercially available in the United States.
Pemvidutide activates GLP-1 and glucagon receptors. GLP-1 is linked to appetite reduction, while glucagon activity is being studied for energy expenditure, liver fat reduction, lipid changes, and broader metabolic effects.
A reconstitution calculator only gives concentration math, not a treatment plan. For example, 12 mg mixed to a final volume of 5 mL gives 2.4 mg/mL; 1.2 mg equals 0.50 mL or 50 U-100 units, 1.8 mg equals 0.75 mL or 75 units, and 2.4 mg equals 1.00 mL or 100 units.
No. Pemvidutide has FDA Breakthrough Therapy Designation for MASH, but that is not the same as approval. It remains a clinical-stage drug candidate, with Phase 3 MASH development planned rather than pharmacy access
Pemvidutide is GLP-1/glucagon based, semaglutide is GLP-1 based, and tirzepatide is GLP-1/GIP based. That makes pemvidutide especially relevant to liver-fat and MASH research, but there are no completed head-to-head approval-level trials proving it is better or safer.
Practical takeaway: If your real goal is weight or metabolic health, the most useful next step is discussing approved treatment options with a clinician rather than relying on an unapproved compound.
Important: This tool is for informational and research-reference purposes only. Not intended for human or veterinary use.